ACADIA Pharmaceuticals (ACAD) : Belmont Global Advisors scooped up 8,000 additional shares in ACADIA Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 38,000 shares of ACADIA Pharmaceuticals which is valued at $1,192,060.ACADIA Pharmaceuticals makes up approximately 2.16% of Belmont Global Advisors’s portfolio.
Other Hedge Funds, Including , Weiss Multi-strategy Advisers reduced its stake in ACAD by selling 15,500 shares or 38.27% in the most recent quarter. The Hedge Fund company now holds 25,000 shares of ACAD which is valued at $784,250. ACADIA Pharmaceuticals makes up approx 0.03% of Weiss Multi-strategy Advisers’s portfolio.Geode Capital Management reduced its stake in ACAD by selling 26,928 shares or 3.99% in the most recent quarter. The Hedge Fund company now holds 648,089 shares of ACAD which is valued at $20,330,552. ACADIA Pharmaceuticals makes up approx 0.01% of Geode Capital Management’s portfolio.Alliancebernstein reduced its stake in ACAD by selling 50,290 shares or 27.25% in the most recent quarter. The Hedge Fund company now holds 134,270 shares of ACAD which is valued at $4,212,050.Cable Hill Partners reduced its stake in ACAD by selling 5 shares or 3.36% in the most recent quarter. The Hedge Fund company now holds 144 shares of ACAD which is valued at $5,255.California Public Employees Retirement System reduced its stake in ACAD by selling 5,100 shares or 3.01% in the most recent quarter. The Hedge Fund company now holds 164,100 shares of ACAD which is valued at $6,099,597. ACADIA Pharmaceuticals makes up approx 0.01% of California Public Employees Retirement System’s portfolio.
ACADIA Pharmaceuticals closed down -0.03 points or -0.09% at $32.1 with 13,67,940 shares getting traded on Thursday. Post opening the session at $32.19, the shares hit an intraday low of $31.525 and an intraday high of $32.69 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, ACADIA Pharmaceuticals reported $-0.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.16 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.47. The company had revenue of $.97 million for the quarter, compared to analysts expectations of $.71 million. The company’s revenue was up 96900.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.39 EPS.
Many Wall Street Analysts have commented on ACADIA Pharmaceuticals. ACADIA Pharmaceuticals was Downgraded by BofA/Merrill to ” Neutral” on Jun 22, 2016.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis Alzheimers disease psychosis Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan has discovered and engaged in the development of small-molecule product candidates such as alpha adrenergic agonists and muscarinic receptors.